VG Life Sciences Inc. (VGLS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 2.18 Million USD | -16.41% |
| 2021 | 2.6 Million USD | -43.95% |
| 2020 | 4.65 Million USD | 20.18% |
| 2019 | 3.87 Million USD | 0.0% |
| 2014 | 3.82 Million USD | 53.45% |
| 2013 | 2.49 Million USD | 40947596.31% |
| 2012 | -6.09 USD | 0.0% |
| 2006 | 2 Million USD | 0.24% |
| 2005 | 2 Million USD | 270.05% |
| 2004 | 541.43 Thousand USD | -93.22% |
| 2003 | 7.98 Million USD | 201.55% |
| 2002 | 2.64 Million USD | -71.41% |
| 2001 | 9.26 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 2.15 Million USD | -1.38% |
| 2023 Q3 | 2.11 Million USD | -3.86% |
| 2023 Q2 | 2.19 Million USD | 2.06% |
| 2022 FY | 2.18 Million USD | -16.41% |
| 2022 Q4 | 2.18 Million USD | 6.88% |
| 2022 Q3 | 2.04 Million USD | 0.0% |
| 2021 Q3 | 3.08 Million USD | 0.0% |
| 2021 FY | 2.6 Million USD | -43.95% |
| 2020 FY | 4.65 Million USD | 20.18% |
| 2019 FY | 3.87 Million USD | 0.0% |
| 2015 Q1 | 4.21 Million USD | 10.24% |
| 2015 Q3 | 3.36 Million USD | -17.74% |
| 2015 Q2 | 4.08 Million USD | -3.14% |
| 2014 Q4 | 3.82 Million USD | 5.02% |
| 2014 FY | 3.82 Million USD | 53.45% |
| 2014 Q1 | 2.81 Million USD | 13.02% |
| 2014 Q2 | 3.23 Million USD | 14.72% |
| 2014 Q3 | 3.64 Million USD | 12.7% |
| 2013 Q4 | 2.49 Million USD | 0.0% |
| 2013 Q1 | 6.09 USD | 0.0% |
| 2013 FY | 2.49 Million USD | 40947596.31% |
| 2012 FY | -6.09 USD | 0.0% |
| 2007 Q3 | 89.82 Thousand USD | -94.09% |
| 2007 Q2 | 1.51 Million USD | -57.05% |
| 2007 Q1 | 3.53 Million USD | 76.1% |
| 2006 Q2 | 5.1 Million USD | 22.42% |
| 2006 FY | 2 Million USD | 0.24% |
| 2006 Q1 | 4.17 Million USD | 108.23% |
| 2006 Q4 | 2 Million USD | -62.96% |
| 2006 Q3 | 5.42 Million USD | 6.15% |
| 2005 Q4 | 2 Million USD | -6.03% |
| 2005 Q3 | 2.13 Million USD | 15.0% |
| 2005 Q2 | 1.85 Million USD | 53.71% |
| 2005 Q1 | 1.2 Million USD | 122.78% |
| 2005 FY | 2 Million USD | 270.05% |
| 2004 FY | 541.43 Thousand USD | -93.22% |
| 2004 Q4 | 541.43 Thousand USD | -50.4% |
| 2004 Q3 | 1.09 Million USD | -84.87% |
| 2004 Q2 | 7.21 Million USD | -5.09% |
| 2004 Q1 | 7.6 Million USD | -4.84% |
| 2003 Q2 | 8.02 Million USD | 243.22% |
| 2003 FY | 7.98 Million USD | 201.55% |
| 2003 Q4 | 7.98 Million USD | -2.58% |
| 2003 Q3 | 8.19 Million USD | 2.19% |
| 2003 Q1 | 2.33 Million USD | -11.75% |
| 2002 Q3 | 6.89 Million USD | -8.45% |
| 2002 Q2 | 7.53 Million USD | 1.69% |
| 2002 Q1 | 7.4 Million USD | -19.1% |
| 2002 FY | 2.64 Million USD | -71.41% |
| 2002 Q4 | 2.64 Million USD | -61.59% |
| 2001 Q2 | - USD | -100.0% |
| 2001 FY | 9.26 Million USD | 0.0% |
| 2001 Q3 | 241.56 Thousand USD | 0.0% |
| 2001 Q1 | 226.71 Thousand USD | 4.07% |
| 2001 Q4 | 9.15 Million USD | 3690.42% |
| 2000 Q4 | 217.85 Thousand USD | 25.03% |
| 2000 FY | - USD | 0.0% |
| 2000 Q3 | 174.23 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 166580.916% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 61.389% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 94.904% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 973.688% |
| Rebus Holdings, Inc. | 305 Thousand USD | -615.049% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 134.593% |
| Qrons Inc. | 351.42 Thousand USD | -520.584% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -250.422% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 94.979% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 10786.495% |
| Skye Bioscience, Inc. | -5.72 Million USD | 138.118% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 86.164% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 47.04% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -442.716% |
| SQZ Biotechnologies Company | -36.23 Million USD | 106.018% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 2.735% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -135.217% |
| Mesoblast Limited | 55.85 Million USD | 96.096% |
| Marizyme, Inc. | 18.56 Million USD | 88.255% |
| Genus plc | 190.6 Million USD | 98.856% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 2.457% |
| Pharming Group N.V. | 109.8 Million USD | 98.014% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -153.522% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -79.662% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -220.721% |
| ContraFect Corporation | -6.02 Million USD | 136.192% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1519.813% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -88.752% |
| IMV Inc. | 7.67 Million USD | 71.568% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 60.361% |
| MultiCell Technologies, Inc. | 90.04 USD | -2422045.713% |
| ONE Bio Corp. | 9.04 Million USD | 75.875% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 397.134% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 83.154% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -59.426% |
| Q BioMed Inc. | 4.06 Million USD | 46.283% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 92.862% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -116.42% |
| Biomind Labs Inc. | 711.4 Thousand USD | -206.564% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 96.398% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -9.078% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 82.97% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -506.294% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1459.97% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -10877.5% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 0.957% |
| GB Sciences, Inc. | 1.74 Million USD | -24.814% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1286.639% |
| HST Global, Inc. | 96.79 Thousand USD | -2153.159% |
| CSL Limited | 10.52 Billion USD | 99.979% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -957.575% |
| Halberd Corporation | 144.72 Thousand USD | -1406.969% |
| Enzolytics Inc. | 981.65 Thousand USD | -122.165% |
| Agentix Corp. | 37.63 Thousand USD | -5695.488% |
| Resverlogix Corp. | 6.45 Million USD | 66.193% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 424.014% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.107% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 104.639% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 69.157% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 19.483% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 124.671% |
| AVAX Technologies, Inc. | -5.9 Million USD | 136.944% |
| Zenith Capital Corp. | 10.06 Thousand USD | -21570.31% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.205% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -988.1% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 8.597% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1225.703% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 12005.776% |
| Kadimastem Ltd | -253.1 Thousand USD | 961.668% |
| Helix BioMedix, Inc. | -2.57 Million USD | 184.859% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 89.244% |
| BioStem Technologies, Inc. | 4.47 Million USD | 51.232% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -983.655% |
| LadRx Corporation | -2.03 Million USD | 207.092% |
| Cell Source, Inc. | 9.23 Million USD | 76.377% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -243.359% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -243.359% |
| NovAccess Global Inc. | 2.17 Million USD | -0.112% |
| Affymax, Inc. | -5.59 Million USD | 138.966% |
| Itoco Inc. | 228.3 Thousand USD | -855.257% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1503.733% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 56.004% |
| Mobile Lads Corp. | 484.23 Thousand USD | -350.383% |
| CytoDyn Inc. | 20.26 Million USD | 89.237% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 337178.825% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 23630.643% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 71.699% |
| SYBLEU INC | 473.71 Thousand USD | -360.383% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 51.068% |
| International Stem Cell Corporation | 2.59 Million USD | 15.795% |
| Bioxytran, Inc. | 1.89 Million USD | -14.85% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3394.304% |
| Cardax, Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 36.491% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 74.501% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -182.278% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 274.472% |
| Neutra Corp. | 52.18 Thousand USD | -4079.01% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 187.622% |
| PureTech Health plc | -167.19 Million USD | 101.304% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 990.498% |
| IXICO plc | -4.44 Million USD | 149.069% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 83.502% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 96.024% |
| CSL Limited | 10.52 Billion USD | 99.979% |
| Cellectis S.A. | -43.81 Million USD | 104.977% |